Brokerages expect Irhythm Technologies Inc (NASDAQ:IRTC) to post earnings per share of ($0.46) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Irhythm Technologies’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.50). Irhythm Technologies posted earnings per share of ($0.29) during the same quarter last year, which indicates a negative year-over-year growth rate of 58.6%. The company is scheduled to report its next earnings report on Wednesday, November 7th.

On average, analysts expect that Irhythm Technologies will report full-year earnings of ($1.91) per share for the current financial year, with EPS estimates ranging from ($2.05) to ($1.75). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.52) per share, with EPS estimates ranging from ($1.82) to ($1.13). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Irhythm Technologies.

Irhythm Technologies (NASDAQ:IRTC) last released its quarterly earnings data on Wednesday, August 1st. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.12). Irhythm Technologies had a negative net margin of 34.38% and a negative return on equity of 53.59%. The company had revenue of $35.50 million during the quarter, compared to the consensus estimate of $32.52 million. During the same quarter in the prior year, the company posted ($0.29) EPS. The company’s revenue for the quarter was up 48.8% compared to the same quarter last year.

A number of research analysts have issued reports on IRTC shares. Zacks Investment Research cut Irhythm Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, July 4th. BMO Capital Markets upped their price objective on Irhythm Technologies to $93.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 10th. BidaskClub raised Irhythm Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, June 13th. Morgan Stanley upped their price objective on Irhythm Technologies from $70.00 to $86.00 and gave the stock an “overweight” rating in a research report on Monday, June 4th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Irhythm Technologies in a research report on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $84.29.

In related news, Director Raymond W. Scott sold 6,877 shares of the company’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of $80.41, for a total transaction of $552,979.57. Following the sale, the director now owns 8,905 shares in the company, valued at $716,051.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Derrick Sung sold 10,000 shares of the company’s stock in a transaction dated Friday, May 18th. The stock was sold at an average price of $70.00, for a total value of $700,000.00. Following the sale, the insider now owns 23,858 shares in the company, valued at approximately $1,670,060. The disclosure for this sale can be found here. Insiders have sold 101,414 shares of company stock valued at $8,266,879 over the last ninety days. 23.30% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRTC. Geode Capital Management LLC raised its holdings in Irhythm Technologies by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 158,418 shares of the company’s stock worth $8,879,000 after acquiring an additional 2,023 shares in the last quarter. Two Sigma Advisers LP bought a new stake in Irhythm Technologies during the fourth quarter worth about $331,000. Two Sigma Investments LP raised its holdings in Irhythm Technologies by 166.4% during the fourth quarter. Two Sigma Investments LP now owns 14,713 shares of the company’s stock worth $825,000 after acquiring an additional 9,191 shares in the last quarter. Macquarie Group Ltd. bought a new stake in Irhythm Technologies during the fourth quarter worth about $608,000. Finally, Shaker Investments LLC OH raised its holdings in Irhythm Technologies by 396.1% during the first quarter. Shaker Investments LLC OH now owns 23,318 shares of the company’s stock worth $1,468,000 after acquiring an additional 18,618 shares in the last quarter.

Irhythm Technologies opened at $83.61 on Tuesday, Marketbeat.com reports. Irhythm Technologies has a 1 year low of $43.03 and a 1 year high of $90.40. The company has a quick ratio of 6.48, a current ratio of 5.58 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -64.32 and a beta of 1.02.

Irhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.

Read More: How to Invest in Growth Stocks

Get a free copy of the Zacks research report on Irhythm Technologies (IRTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.